Search - tctmd.com

Displaying 1 - 20 of 159

Sort: Relevancy | Date

News Industry News

SMT’s Hydra TAVR Valve Demonstrates Sustained Safety, Durability, and Hemodynamic Performance at 5 Years

November 19, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Industry News

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

October 29, 2025

News Industry News

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

September 15, 2025

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Industry News

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients

June 18, 2024

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

L.A. McKeown

October 31, 2023

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Caitlin E. Cox

October 27, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News ESC 2023

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

Michael O'Riordan

August 26, 2023

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Michael O'Riordan

March 01, 2021

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

Advertisement

SMT’s Hydra TAVR Valve Demonstrates Sustained Safety, Durability, and Hemodynamic Performance at 5 Years

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

What’s Going to Be Big at TCT 2024?

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content